From galas to fashion shows, these are the top charity events coming up this year.Queen Latifah has been a regular at The ...

Members of the Leukemia and Lymphoma Society discussed the importance of educating others, fundraising and spreading ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

Students from high schools in the Greater Lafayette area came together Thursday to compete in an annual cupcake bake-off for a $1,000 prize.

For 24 years, the Lymphoma, Leukemia & Myeloma Congress has stood as the premier educational conference dedicated to hematologic malignancies. Over 75 experts from around the globe gather in New ...

A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...

Risk factors for chronic lymphocytic leukemia (CLL) include having a family history of CLL, being over the age of 50, exposure to certain chemicals, your biological sex, and your race. Chronic ...